All In Biotech

Drug Trial Radar · NCT07804303

Bioequivalence Study of Budesonide/Formoterol Inhalation Powder in Healthy Participants

A Randomized Crossover Bioequivalence Study of Budesonide/Formoterol Inhalation Powder in Healthy Participants Under Fasting Conditions

Last checked: Nov 20, 2026Latest source record: Sep 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

30

Actual

Start

Jan 13, 2024

Primary completion

Jan 22, 2024

Study completion Jan 24, 2024

Sponsor

Sponsor type
Industry
First posted
Sep 4, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The goal of this study is to learn if a new formulation of Budesonide/Formoterol Inhalation Powder (160μg/4.5μg), manufactured by Shanghai New Huanghe Pharmaceutical Co., Ltd., works the same as the already approved reference product, Symbicort® Turbuhaler® (160μg/4.5μg), in the body. It will also learn about the safety of the new formulation. The main questions it aims to answer are: * How quickly and how much of the study drug gets into the blood after inhalation, compared with the reference product? * What medical problems do participants have when taking the study drug? Researchers will compare the new formulation to the reference product (the already approved treatment) to see if they are bioequivalent. Participants will: * Be randomly assigned to receive either the new formulation or the reference product in the first period, then switch to the other in the second period * Take a single dose of 2 inhalations in each period, with a 4-day washout period between doses * Have 22 blood samples collected over 36 hours after each dose to measure drug levels in the blood * Visit the clinic for checkups, including vital signs, physical examinations, and laboratory tests * Be monitored for any side effects throughout the study

Conditions

  • Asthma
  • Chronic Obstructive Pulmonary Disease (COPD)

Interventions

  • Budesonide and Formoterol Fumarate Powder for Inhalation (II) (Test)Drug

    160 μg/4.5 μg, administered as 2 inhalations, manufactured by Shanghai New Huanghe Pharmaceutical Co., Ltd.

  • Budesonide and Formoterol Fumarate Powder for Inhalation (II) (Reference)Drug

    160 μg/4.5 μg, administered as 2 inhalations, manufactured by AstraZeneca AB.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum Observed Concentration (Cmax)Time frame: 0 to 36 hours post-dose in each period
  2. Area Under the Plasma Concentration-Time Curve from Time 0 to the Last Measurable Concentration (AUC0-t)Time frame: 0 to 36 hours post-dose in each period
  3. Area Under the Plasma Concentration-Time Curve from Time 0 Extrapolated to Infinity (AUC0-∞)Time frame: 0 to 36 hours post-dose in each period

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Nanjing Gaoxin Hospital

    Nanjing, Jiangsu, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.